Sildenafil Basi

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sildenafil Basi

Quick Facts

Property Description
Active ingredient Sildenafil (Sildenafil citrate)
Form Film-coated tablet
Pharmacological class Selective Phosphodiesterase type 5 (PDE5) Inhibitor
Common use Supports function requiring enhanced blood flow
Origin Synthetic compound

Sildenafil Basi: Classification and Active Composition

Sildenafil Basi is a prescription-only medicine whose active ingredient is Sildenafil, a substance generally provided as the salt, Sildenafil citrate. The drug is definitively classified by its primary mode of action as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This mechanism of action is characterized by its effect on vascular tone. The specific chemical structure of the compound places it within the family of synthetic pyrazolo[4,3-d]pyrimidine derivatives. It is manufactured as a single-ingredient product, containing only Sildenafil as the active pharmaceutical component along with necessary excipients required for its final presentation. The formulation is clinically recognized for achieving systemic absorption necessary for its intended action.

What is the Pharmaceutical Form and General Purpose?

Sildenafil Basi is produced as an oral preparation in the form of a film-coated tablet, making it suitable for oral administration in adult male patients. The general purpose of the medicine stems directly from its pharmacological class. As a selective PDE5 inhibitor, Sildenafil modulates the concentration of cyclic guanosine monophosphate (cGMP) in specific smooth muscle tissues by blocking the enzyme responsible for cGMP degradation. This molecular action promotes smooth muscle relaxation and results in vasodilation, which is the widening of blood vessels. This inhibition ultimately supports functions in patients that rely on enhanced blood flow to targeted areas. The drug's primary physiological objective is therefore to support a stronger and more sustained physical response in situations where optimizing blood supply is the key factor.

Regulatory References

  1. European Medicines Agency (EMA) confirms this mechanism of action
  2. National Institutes of Health (NIH) confirms that this inhibition ultimately supports functions

What side effects are possible with Sildenafil Basi?

Possible side effects and safety information

The safety profile of Sildenafil Basi is described by regulatory authorities based on the frequency and the physiological system affected. The most frequently documented adverse reaction in regulatory safety data is Headache, which is classified as Very Common (ge 1/10).

Common (ge 1/100 to <1/10) adverse effects officially listed in prescribing information often relate to the vascular and gastrointestinal systems, including Flushing, Dyspepsia, Nasal congestion, and visual disturbances like Visual color distortions.


Documented Safety Classifications

The medicine's regulatory safety structure includes the explicit identification of rare but serious adverse reactions and formal restrictions on use.

Category Description from Regulatory Documents
Serious Adverse Reactions Includes documented reports of Priapism (prolonged erection), Sudden Visual Loss (e.g., NAION), Sudden Hearing Loss, and serious Cardiovascular Events (e.g., Myocardial Infarction, Stroke) in temporal association with use.
Safety-Related Restrictions Use is strictly contraindicated with concurrent Nitrates or Nitric Oxide Donors, and with the guanylate cyclase stimulator Riociguat. It is also restricted in patients with a history of NAION or recent Myocardial Infarction or Stroke (within 6 months).
Population Safety Notes Use is contraindicated in patients with severe hepatic impairment. Dosage adjustments are advised for individuals with severe renal impairment (CLcr < 30 mL/min).

These official safety data points define the risk profile and formal conditions under which the medicine may be administered, strictly differentiating between frequently expected reactions and absolute safety constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sildenafil (Sildenafil citrate) overdose primarily describes the need for emergency action due to dose-dependent physiological effects.

Overexposure, often involving doses higher than prescribed, generally results in an exaggeration of documented adverse events. These may include intensified headache, pronounced flushing, increased dizziness, and more significant visual disturbances.

Immediate Medical Help Is Required When:

Condition Regulatory Mandate
Prolonged Erection (Priapism) Seek immediate medical assistance if an erection lasts 4 hours or longer to prevent permanent tissue damage.
Cardiovascular/Sensory Emergency Seek emergency medical attention for sudden loss of vision, sudden decrease or loss of hearing, or symptoms suggestive of severe hypotension (e.g., syncope or fainting) [FDA Labeling].
Accidental Overexposure Contact emergency medical services or a Poison Control center immediately following any accidental overdose.

Overdose Management

Official documents confirm that no specific antidote is known for Sildenafil overdose. Therefore, the required clinical strategy is symptomatic and supportive treatment, involving the continuous monitoring of vital signs to manage effects like severe hypotension.

Patients with pre-existing conditions such as severe renal or hepatic impairment have reduced drug clearance, which can lead to higher plasma concentrations and an increased risk of toxicity following overdose.

Therapeutic Uses of Sildenafil Basi

What Sildenafil Basi Treats: Main Uses and Benefits

Sildenafil Basi may be considered in two distinct therapeutic domains where supportive management of symptoms is relevant and assists with maintaining functional stability. The medication is applied in addressing two primary categories of conditions: erectile dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

Primary Therapeutic Benefits

For sexual health, this medicine is applied in addressing the symptom cluster of erectile dysfunction, which is the inability to achieve or sustain an adequate erection. It supports the physiological response for erection, which may assist with maintaining functional stability in this domain. For cardiopulmonary health, it is considered relevant in settings marked by the heightened symptoms of PAH, a chronic condition involving abnormally high blood pressure in the lung arteries. It helps ease symptoms like dyspnea and fatigue that create noticeable physiological strain.

This supportive therapeutic benefit may assist with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods. The medication is generally used to help manage symptoms that interfere with physical capacity, thereby supporting patient well-being.


Quick Fact: Relief for Key Symptom Clusters

Property Description
Symptom Domain 1 Inadequate penile rigidity and functional strain during sexual activity.
Symptom Domain 2 Dyspnea and fatigue interfering with physical capacity in PAH.
Use Context (ED) Situational support for functional response.
Use Context (PAH) Chronic, long-term symptomatic management.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sildenafil Basi — Official Regulatory Information

The eligibility profile for Sildenafil is strictly defined by government regulatory documents (e.g., FDA, EMA) and is based on potential safety risks, co-administered medications, and pre-existing medical conditions.

Absolute Exclusions (Contraindications)

Population/Condition Regulatory Status
Patients using organic nitrates (in any form) or riociguat (a guanylate cyclase stimulator) Contraindicated (Risk of severe hypotension)
Patients with a known hypersensitivity to sildenafil Contraindicated
History of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Contraindicated
Severe cardiovascular disorders (e.g., unstable angina, severe cardiac failure) where sexual activity is inadvisable Contraindicated
Recent stroke or myocardial infarction (within the last 6 months) Contraindicated
Severe hepatic impairment or hypotension (BP < 90/50 mmHg) Contraindicated (Safety not established)

Eligibility-Related Restrictions

Population/Condition Regulatory Guidance
Patients with severe renal impairment or mild to moderate hepatic impairment Lower starting dose should be considered
Patients with anatomical deformation of the penis or priapism-predisposing conditions (e.g., sickle cell anaemia) Use with caution
Pediatric use (for Erectile Dysfunction) Not indicated

Pregnancy and Lactation

Safety is not established. Use during pregnancy is only advised if the potential benefit outweighs the risk. It is not known if Sildenafil is excreted in human milk, thus caution is advised for nursing women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sildenafil Basi is primarily defined by the risk of potentiating hypotensive effects and pharmacokinetic interactions related to its metabolism.

Contraindicated Combinations

Co-administration with nitric oxide donors (e.g., nitroglycerin, isosorbide dinitrate) in any form is strictly contraindicated. This combination significantly potentiates the vasodilatory effect, leading to severe, symptomatic drops in blood pressure. The simultaneous use of guanylate cyclase stimulators (e.g., riociguat) is also contraindicated for the same reason.

Use with Caution

Interactions that require caution, monitoring, or dose adjustment are linked to agents that affect Sildenafil's metabolism and agents that also lower blood pressure.

  • CYP3A4 Inhibitors: Strong inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme (e.g., ritonavir, ketoconazole, erythromycin) increase Sildenafil plasma concentrations. This necessitates considering a reduced initial dose of Sildenafil. A specific maximum dose of Sildenafil is required when co-administered with ritonavir.
  • Alpha-blockers: Concomitant use with alpha-blockers can lead to symptomatic low blood pressure in susceptible patients, particularly within four hours of Sildenafil dosing. Sildenafil should only be started in patients who are haemodynamically stable on their alpha-blocker therapy.
  • Other Agents Affecting Hemostasis: Sildenafil potentiates the antiaggregatory effect of sodium nitroprusside in vitro, and caution is advised regarding use in patients with existing bleeding disorders or active peptic ulceration. Co-administration with other treatments for erectile dysfunction is not recommended.

Mechanism of Action

Blocking the PDE5 Enzyme to Preserve cGMP Signaling

The core mechanism of Sildenafil Basi involves acting as a selective competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is predominantly localized in the smooth muscle cells of specific vascular beds, including the penile corpus cavernosum and the pulmonary vasculature. By binding to and blocking PDE5, the drug prevents the breakdown of the second messenger cyclic guanosine monophosphate (cGMP). This action results in the preservation and intracellular accumulation of cGMP.

Context-Dependent Vascular Smooth Muscle Relaxation

Elevated cGMP levels trigger a series of downstream events, including the activation of Protein Kinase G (PKG), which leads directly to a change in vascular smooth muscle tone. The resultant reduced intracellular calcium and altered myosin light chain activity cause the smooth muscle to relax, resulting in vasodilation (widening of blood vessels). This mechanism is dependent on the prior or concurrent release of Nitric Oxide (NO) to initiate the cascade, meaning Sildenafil Basi potentiates the natural NO-mediated signaling pathway.

Resulting Hemodynamic Changes

This molecular and cellular cascade produces a localized, regional increase in blood flow capacity within the targeted vascular regions. This adjustment of regional hemodynamics, or blood flow dynamics, is the final physiological consequence of the drug's mechanism of action.

Dosage and Administration Information

How to Use Sildenafil Basi

The administration of Sildenafil Basi is determined by the specific condition being managed, which necessitates two distinct regimens: intermittent use for one context and fixed-schedule use for another. The medicine is primarily for oral administration as a film-coated tablet or oral suspension; however, an intravenous form is approved for use in specific clinical settings.

Official Dosing and Frequency

The dosing schedule is strictly dependent on the use context. For the as-needed regimen, the standard recommended starting dose is 50 mg, which may be adjusted between 25 mg and a maximum of 100 mg once per day. For the fixed-schedule regimen, the recommended starting dose is 20 mg administered three times a day (TID), typically 4–6 hours apart, and may be escalated up to a maximum of 80 mg TID.

Administration Conditions

Feature Guideline
Intake Timing The intermittent dose is generally taken 30 minutes to 4 hours prior to anticipated activity. The fixed-schedule dose is taken every 4–6 hours.
With/Without Food Can be taken with or without food. However, consuming a high-fat meal may delay the onset of action for the intermittent regimen.
Dose Adjustments A 25 mg starting dose is considered for the intermittent regimen when used in older adults (≥65 years) or those with severe renal or hepatic impairment.
Procedural Note For the intermittent regimen, sexual stimulation is required for the physiological action to occur.

These instructions define the protocol for proper use, establishing both the specific dose ranges and the frequency limitations, such as the maximum of once daily for the intermittent regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for Sildenafil Basi


Evidence for use in Erectile Dysfunction (ED)

The evidence base for Sildenafil Basi in the context of erectile dysfunction (ED) is built upon numerous short-term randomized controlled trials (RCTs). These studies compared the active ingredient against an inactive substance in a double-blind setting. Researchers monitored a diverse population of adult men with functional limitations, including those with associated conditions such as diabetes or hypertension. These trials monitored outcomes reflecting daily functioning, measured through validated tools like the International Index of Erectile Function (IIEF) and other patient-reported outcomes.

The main body of trials gathered data on patient-reported outcomes related to functional status after a short period of use. Analysis of the collected data indicated findings related to patient-reported outcomes in the observed populations during short-term study periods.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research into the use of Sildenafil Basi for Pulmonary Arterial Hypertension (PAH), a condition marked by functional limitations, has focused on a combination of short-term RCTs and longer-term observational studies. The primary controlled studies were typically short-term, lasting 12 to 16 weeks, and were used in research exploring short-term symptom changes. These trials involved adult patients with PAH and measured outcomes related to systemic or functional imbalance.

The studies monitored outcomes reflecting daily functioning, most notably the 6-Minute Walk Distance (6MWD). Research also examined a composite outcome known as time to clinical worsening, an outcome related to acute changes in the observed populations over the trial duration. Findings provided data on measured outcomes related to the 6MWD after 12 to 16 weeks of follow-up.


Long-Term Studies and Follow-up Data

While the primary findings for both indications come from short-term controlled trials, the research base also includes extended follow-up data. For the PAH indication, open-label extension studies have followed patients over defined time intervals spanning several years. However, the long-term effects are not fully established by the same rigorous standard as the short-term findings because these extended studies are typically open-label and lack a concurrent placebo control. Consequently, the certainty remains lower regarding the continuous maintenance of findings in these longer observational settings.

What the Research Landscape Identifies as Uncertain

A key research limitation is that the results apply only to the populations studied, and extrapolation to patients outside of these study parameters is uncertain. For both indications, the follow-up durations were limited in the most rigorous controlled trials, meaning long-term effects are not fully established by controlled research. Furthermore, evidence suggests that better characterization of all-cause mortality in the PAH setting is needed, as comparative evidence in some pooled analyses is lacking or mixed.

Frequently Asked Questions (FAQ)

Common questions about Sildenafil Basi (FAQ)


Q: How long do the effects of Sildenafil Basi typically last?

A: Studies on the drug’s processing in the body indicate that its half-life—the time it takes for half of the medication to leave the system—is approximately 3 to 5 hours. The highest concentration of the drug in the bloodstream typically occurs about one hour after administration.


Q: Is Sildenafil Basi the same thing as Viagra?

A: Sildenafil Basi contains the identical active ingredient: sildenafil. The medication Viagra is the original brand-name product also containing sildenafil. Both products are classified as PDE5 inhibitors, meaning they share the same pharmacological mechanism of action.


Q: What's the difference between Sildenafil Basi and Tadalafil?

A: Sildenafil Basi contains sildenafil, while Tadalafil (the active ingredient in Cialis) is a different chemical compound. Both belong to the same pharmacological class, PDE5 inhibitors. They both work by blocking the PDE5 enzyme to promote blood vessel relaxation and increased blood flow in specific areas of the body.


Q: Can alcohol reduce the effectiveness of Sildenafil Basi?

A: Official product information notes that sildenafil can cause a drop in blood pressure. Combining it with alcohol may further increase the risk of symptoms associated with low blood pressure, such as dizziness or facial flushing. Excessive alcohol consumption may also independently complicate erectile function.


Q: What happens if I take Sildenafil Basi on a full stomach?

A: The medication can be taken with or without food. However, consuming a meal that is particularly high in fat may slow down the absorption of the drug into your bloodstream. This may result in a delay in the onset of the drug's action.


Q: How often can Sildenafil Basi be taken safely?

A: For the treatment of erectile dysfunction (the as-needed regimen), official dosing recommendations state that the medicine should be taken no more frequently than once per day.


Q: Are there any known long-term side effects from using Sildenafil Basi regularly?

A: The primary clinical trials for the drug's initial approval were short-term. While some patients have participated in open-label extension studies for several years, the full long-term safety profile is not established to the same rigorous standard as the short-term findings because the extended studies typically lack a placebo control.


Q: What should I do if Sildenafil Basi doesn't seem to be working for me?

A: Official labeling notes that the initial dose is adjustable based on observed efficacy and tolerability. The decision to adjust the prescribed dose is a medical decision that requires professional guidance, not a self-administered change.


Q: Can Sildenafil Basi be used for pulmonary arterial hypertension in children?

A: Sildenafil is indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients 1 year of age and older. This use requires specific protocols for dosage and medical supervision, which is administered by specialized healthcare providers.


Q: What clinical trials support the use of Sildenafil Basi?

A: The efficacy of Sildenafil Basi is supported by multiple short-term randomized controlled trials (RCTs). These studies measured patient-reported outcomes for erectile dysfunction and objective functional outcomes, such as the 6-Minute Walk Distance (6MWD), for pulmonary arterial hypertension.


Q: What are the signs of a serious allergic reaction to Sildenafil Basi?

A: The medicine is contraindicated in patients with a known hypersensitivity to any of its components. Serious reactions may include symptoms like swelling of the face, lips, or tongue. Official guidance recommends seeking emergency medical help if these symptoms occur.


Q: Are there any foods or drinks I should avoid while taking Sildenafil Basi?

A: Patients are generally advised to limit or avoid grapefruit and grapefruit juice, as these may increase the levels of sildenafil in the blood, potentially raising the risk of side effects. Additionally, consuming a high-fat meal can delay the drug’s onset of action.


Q: Does Sildenafil Basi affect fertility or sperm count?

A: Studies have not indicated that sildenafil negatively affects fertility. Clinical data collected showed no significant differences in sperm quality, including motility, count, or morphology, when compared to a placebo during short-term study periods.


Q: Can Sildenafil Basi be purchased without a prescription in some countries?

A: Sildenafil Basi is classified as a prescription-only medicine by most major regulatory bodies in regions like the European Union and the United States. Its availability without a prescription depends entirely on specific regulatory decisions in individual countries for particular strengths or formulations.


Q: What happens if I miss a dose of Sildenafil Basi (when used for pulmonary hypertension)?

A: For patients on a fixed schedule (such as for pulmonary hypertension), official labeling advises taking the next dose as scheduled if one is missed. For frequently missed doses, professional guidance is necessary to determine the next steps for treatment continuity.


Q: Is Sildenafil Basi addictive?

A: Sildenafil is a prescription drug and is not classified as a controlled substance under the US Controlled Substances Act or similar international frameworks. The drug is not known to produce dependency or the euphoric effects associated with addictive substances.


Q: Is there any research on Sildenafil Basi being used for Raynaud's phenomenon?

A: The drug is not formally indicated for the treatment of Raynaud’s phenomenon. However, scientific literature has explored sildenafil's role as a treatment option for this condition, particularly when secondary to systemic sclerosis, due to its established vasodilatory effect.


Q: What is the general success rate of Sildenafil Basi for erectile dysfunction?

A: Clinical trials demonstrated that treatment improved functional outcomes in patients with erectile dysfunction compared to placebo. The success rate in the general population can vary widely based on the underlying cause and individual severity of the condition.


Q: Do generics of Sildenafil Basi work as well as the brand name?

A: A generic medicine must contain the identical active ingredient and be shown to be bioequivalent to the original branded product before it can be approved. This means the generic is expected to provide the same clinical benefit and work in the body in the same way.


Q: How does age affect how Sildenafil Basi works?

A: The core mechanism of action is generally not altered by age. However, a lower initial dose is typically considered for older adults, defined as those 65 years and over. This adjustment accounts for age-related changes in how the body processes the medicine.


Q: Is it safe to take Sildenafil Basi with herbal supplements?

A: Sildenafil is metabolized by a liver enzyme called CYP3A4. Some herbal supplements, such as St. John's wort, are known to influence this enzyme and could potentially alter the concentration of Sildenafil in the bloodstream. Concomitant use with untested supplements is generally not recommended.


Q: Can Sildenafil Basi interact with commonly used over-the-counter pain relievers?

A: Official labeling identifies specific major drug contraindications. Commonly used over-the-counter pain relievers, such as ibuprofen or acetaminophen, are not typically listed as having major interactions in the official product information.


Q: What is the recommended storage for Sildenafil Basi tablets?

A: Official requirements mandate that the tablets be stored at controlled room temperature, generally 20 C to 25 C. The medicine must be kept in its original container, protected from moisture, and stored out of the sight and reach of children.


Q: What's the mechanism behind Sildenafil Basi's effect on lung arteries?

A: The mechanism of action supports the treatment of pulmonary arterial hypertension (PAH) because the PDE5 enzyme is prevalent in the smooth muscle of the lung's blood vessels. By inhibiting PDE5, the drug promotes localized vasodilation (widening) in the lungs, which helps to reduce pressure in the pulmonary arteries.


Q: How much does diet impact the efficacy of Sildenafil Basi?

A: Official information indicates that a high-fat meal can delay the onset of action of Sildenafil Basi, meaning it may take longer to start working. However, the product labeling does not explicitly state that diet otherwise reduces the overall final effectiveness (efficacy) of the absorbed dose.


Q: Are there any common reasons why Sildenafil Basi might not work the first time?

A: For the treatment of erectile dysfunction, the drug requires sexual stimulation for the desired physiological action to occur. Efficacy may also be affected by underlying medical conditions or if the prescribed dose is too low.


Q: Does Sildenafil Basi contain lactose or other common allergens?

A: The inactive ingredients (excipients) in Sildenafil Basi tablets vary slightly by manufacturer. The tablet core may contain common ingredients such as lactose. The specific Patient Information Leaflet should be referenced for individuals with known allergies or intolerances.


Q: Can young adults take Sildenafil Basi for erectile dysfunction?

A: Sildenafil Basi is indicated for use in adult male patients with erectile dysfunction. While the standard minimum age for adult use is 18 years, the use of the drug in young adult populations must be based on a clinical assessment by a healthcare provider.

How should Sildenafil Basi be stored and disposed of?

Sildenafil Basi Storage and Disposal Instructions

Sildenafil Basi tablets must be stored according to specific regulatory requirements to maintain product stability.

Storage Requirements

The medication requires controlled room temperature, generally defined as 20 C to 25 C. The tablets must be protected from moisture and excessive heat. It is mandatory to store the product in its original container and always keep it out of the sight and reach of children.

Disposal Requirements

Disposal must be conducted in accordance with local requirements for pharmaceutical waste. Unused or expired Sildenafil Basi must not be disposed of via wastewater or household waste. Instead, unused medicine should be returned to a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sildenafil Basi found in:

A-Z Index: